Dassault Systèmes has completed the acquisition of Medidata, a digital clinical solutions company with a leading clinical trial platform.
The acquisition of Medidata will provide Dassault with a leading expertise in cloud-based solutions, which aid in the smarter development and commercialisation of treatments coming through the pipeline.
“Together with Medidata’s solutions and its great talents that we are delighted to welcome, we bring an unmatched combination of assets to reinforce our vision, science-based culture, and life sciences industry knowledge and know-how. Medidata will be a core brand in our information intelligence domain,” said Bernard Charlès, Vice Chairman and CEO, Dassault Systèmes.
“By combining data intelligence and simulation, we power smarter therapeutics for healthier people. The inclusive and multi-discipline 3DEXPERIENCE platform will be key for healthcare innovators to anticipate and address the needs of the industry’s transformation toward affordable precision healthcare in the 21st century.
“The virtual world will push the bounds of possibilities to transform not only research and science, but also the entire pharmaceutical and medical device industry and medicine, in general. We made virtual twins of cars and airplanes possible. We will do the same for the human body.”
Medidata will now operate as a Dassault Systémes brand, powered by the 3DExperience platform. The life sciences industry will become Dassault’s second largest business, after transportation and mobility, while advancing sustainable innovation in the industry through the use of biological, chemical and materials science, clinical trials and real-world data on the cloud.
Under the terms of the agreement, Dassault Systémes acquires all of the issued and outstanding common shares of Medidata, for $92.25 per share in cash, representing a total value of around $5.8bn.